Compare McCormick & Company, Incorporated (MKC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novavax Inc — how do they compare? McCormick & Company, Incorporated trades at $44.96 (market cap $12.39B), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: McCormick & Company, Incorporated is far larger — about 6.8× Novavax Inc's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Novavax Inc for 59 Days on average.
| MKC | NVAX | |
|---|---|---|
Market Cap | $12.39B | $1.82B |
Volume | 6,140,872 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $71.65 | $12.56 |
52-Week Low | $44.14 | $6.22 |
Typical Hold Time | 67 Days | 59 Days |
Enterprise Value | $17.07B | $1.39B |
Dividend Yield | 4.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.005, down 0.54% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, supported by the McCormick de Mexico acquisition. Valuation metrics appear attractive with a P/E of 8.31 and net income margin of 19.39%, while analyst consensus shows a mixed but predominantly hold rating.
The stock presents value opportunities with below-sector P/E ratios and consistent dividend payments, but faces technical headwinds and competitive pressures. Upside potential exists toward the $53.50 consensus target, though investors should monitor integration execution and consumer spending trends given the bearish technical indicators and mixed analyst sentiment.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
